Autopsy report · NCT05436990

Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

“According to the protocol criteria, during the Phase 1 analysis, the registered participants' imaging evaluation responses did not meet the criteria, leading to an early termination”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Yonsei University

Sponsor type

University, hospital or other

Conditions

Acral Melanoma; Mucosal Melanoma

Interventions

Pembrolizumab, Vactosertib

Participants

14

Sites

1

Countries

South Korea

Trials that died the same way

• Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)
  “Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.” (61% match in meaning)
• Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
  “Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.” (61% match in meaning)
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)
  “Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.” (60% match in meaning)
• A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
  “The response rate observed in the phase 1 portion of the study did not merit further evaluation in phase 2 portion of the study.” (60% match in meaning)
• Reparixin in COVID-19 Pneumonia - Efficacy and Safety
  “The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.